Skip to main content
. 2021 May 27;12(15):4463–4477. doi: 10.7150/jca.60008

Figure 1.

Figure 1

Low MST4 expression correlates with HCC progression and poor prognosis. (A) Representative images of MST4 immunohistochemical (IHC) staining in HCC specimens (n=325) with different TNM stages. (B) The percentages of cases with high or low expression of MST4 according to different TNM stages of HCC. (C) Representative images of MST4 IHC staining in HCC specimens (n=325) with different clinical stages and histological grades. (D) The percentages of cases with high or low expression of MST4 according to different clinical stages and histological grades of HCC. (E) Kaplan-Meier survival curves of overall survival (OS) in 85 HCC patients with high MST4 expression (red line) and low MST4 expression (green line) (Log-rank test; P=0.021). (F) Univariate and multivariate analyses of prognostic indicators in HCC (n=85). (G) The correlation of MST4 expression with survival time for HCC patients stratified by clinical stage I-II (upper panel) (Log-rank test; P=0.725) and clinical stage III-IV (lower panel) (Log-rank test; P=0.005). Data are mean ± SEM (*P< 0.05, **P <0.01, ***P <0.001).